The breadth of independent research supports vonoprazan's scientific credibility, but no immediate catalyst for stock movement. Monitor for potential label expansion or competitive positioning based on future regulatory actions.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 20 $11.87entry
- T+1 · 6mo ago −2.44%α −2.64% · $11.58
- T+5 · 6mo ago −9.52%α −10.76% · $10.74
- T+20 · 5mo ago −8.34%α −9.08% · $10.88
- T+60 · 3mo ago −19.29%α −24.30% · $9.58
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Phathom Pharmaceuticals announced the presentation of 31 vonoprazan-related abstracts at DDW 2026, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study recognized as a Poster of Distinction. The data covers GERD, H. pylori eradication, long-term safety, and post-endoscopic care, but no new regulatory actions or financial guidance were provided.
Key Facts
- 31 vonoprazan-related abstracts presented at DDW 2026, including 28 independent investigator-initiated studies
- Phathom-sponsored analysis from Phase 3 pHalcon-NERD-301 study recognized as Poster of Distinction
- Data covers GERD, H. pylori eradication, long-term safety, and post-endoscopic submucosal dissection use
- No new FDA decisions, label expansions, or financial updates announced
Financial Impact
No financial impact from this press release; revenue and guidance unchanged.
Risk Factors
- Investor expectations for near-term label expansion may be disappointed if no FDA action follows
- Competitive pressure from PPIs and other PCABs may limit commercial uptake
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298395 |
Track record
16 reports on PHAT
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +36.43% at T+60 after the Jul 30, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $6.28 Now $5.88 −6.37% settles Nov 18
- Nov 2, 202614d ago SC 13D/A Neutral 3/10 Entry $5.74 to $5.45 Now $5.88 +2.44% ▼ −5.14% −4.55% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 5/10 Entry $6.22 to $5.08 Now $5.88 −5.47% ▼ −18.33% −13.60% vs SPY
- Oct 26, 202621d ago 8-K Bearish 5/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 23, 202624d ago 8-K Bearish 6/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 19, 202628d ago Press Release Neutral 1/10 Entry $7.01 Now $5.88 −16.12% No price data
- Sep 29, 20266w ago 8-K Neutral 4/10 Entry $7.30 to $6.81 Now $5.88 −19.45% ▼ −6.71% −8.63% vs SPY
- Jul 30, 202615w ago 8-K Mixed 5/10 No price data
- Jul 30, 202615w ago Press Release Bearish 6/10 Entry $9.03 to $8.39 Now $5.88 +34.88% ▲ +7.09% +10.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers